生脉养心方治疗气血两虚型急性冠脉综合征  

Clinical Efficacy of Shengmai Yangxin Fang for Treating Patients with Acute Coronary Syndrome in Syndrome of Asthenia of Qi and Blood

作　　者：杨满菊[1] 

机构地区：[1]河南省新乡市中心医院,河南新乡453000

出　　处：《中国实验方剂学杂志》2012年第14期281-283,共3页Chinese Journal of Experimental Traditional Medical Formulae

摘　　要：目的:观察用生脉养心方治疗气血两虚型急性冠脉综合征(ACS)患者的临床疗效及安全性。方法:90例气血两虚型ACS患者随机分为治疗组和对照组。所有患者均给予西医基础治疗方案,治疗组在西医基础治疗方案的基础上给予生脉养心中药煎剂治疗,对照组仅采用西医基础治疗方案。治疗1个疗程后进行疗效评估。比较两组治疗前后心功能改善、心绞痛发作时间及发作频率,记录治疗期间不良心血管事件的发生。结果:治疗组临床疗效有效率为91.1%,显著高于对照组(53.3%),两组临床疗效有效率比较有显著性差异(P<0.01)。两组治疗后心脏左室射血分数(LVEF)、E峰A峰比(E/A)及心输出量(CO)显著上升,与治疗前比较均有显著性差异(P<0.05);且治疗组与对照组比较有显著性差异(P<0.05)。治疗后,两组心绞痛发作次数和持续时间均明显降低,与治疗前比较有显著性差异(P<0.05);且治疗组与对照组比较有显著性差异(P<0.05)。治疗组不良事件发生率显著低于对照组,相比较有显著性差异(P<0.05)。结论:生脉养心方治疗气血两虚型急性冠脉综合征是安全、有效的。Objective：To observe the clinical efficacy and safety of Shengmai Yangxin fang for treating the patients with acute coronary syndrome（ACS） in syndrome of asthenia of qi and blood.Method：Ninety cases of patients with ACS in syndrome of asthenia of qi and blood were randomly divided into treatment group and control group.The all patients were given basic treatment of western,the treatment group was given the treatment of Shengmai Yangxin fang,the control group was given only basic treatment of western.The clinical efficacy was evaluated after a course of treatment.The cardiac function,angina pectoris and frequency of attacks of the two group were compared before treatment and after treatment,the adverse cardiovascular events were recorded during treatment.Result： The effective rate of treatment group was 91.1%,the control group was 53.3%,the difference was significant between the two groups（P 0.01）.After treatment the left ventricular ejection fraction（LVEF）,CO and E/A of the two groups increased significantly,compared with the prior-treatment the difference was significant（P 0.05）,and the difference was significant between the two groups（P 0.05）.After treatment the angina attack frequency and duration of the two groups were significantly reduced,compared with pre-treatment the difference was significant（P 0.05）,and the treatment group compared with the control group the difference was significant（P 0.05）.The incidence of adverse events of treatment group was significantly lower than the control group,he difference was significant（P 0.05）.Conclusion： The Shengmai Yangxin fang for treating the patients with ACS in syndrome of asthenia of Qi and Blood is safe and effective.

关 键 词：生脉养心方 急性冠脉综合征 气血两虚型 

分 类 号：R287[医药卫生—中药学]